Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
Marina Biotech, Inc. (Nasdaq: MRNA) reported Q1 loss of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $214 million versus the consensus estimate of $150 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) spreader of 1K contracts of September 25 weekly 157.50 and 165 calls as share price up 10.5%
- LuxExperience B.V. (LUXE) Misses Q2 EPS by 11c
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share